Dad Type 2 Diabetes Medications Marketed in Canada (v. Jan 27, 2023)

PAD Refills February 2023

Generic name, brand name, available strengths	Health Canada adult starting dose (range) ¹ See Canadian monographs for titration details		te annual cost ² Care coverage
METFORMIN			
metformin Glucophage, generics 500, 850 mg	500 mg PO BID; 850 mg PO once daily (1500-2550 mg/day) ³	\$20-40	Regular benefit
metformin ER Glumetza, generics 500, 1000 mg	1000 mg ER PO once daily (1000-2000 mg/day)	\$400-\$800	Non-benefit
SULFONYLUREAS (SU)			
glyburide generics 2.5, 5 mg	2.5 mg PO once daily > 60 years 5 mg PO once daily < 60 years (2.5-20 mg/day)	\$15-\$90	Regular benefit
gliclazide Diamicron, generics 80 mg	80 mg PO BID (80-320 mg/day)	\$75-\$150	Limited Coverage
gliclazide MR Diamicron MR, generics 30, 60 mg	30 mg MR PO once daily (30-120 mg/day)	\$40-\$50	Plan W regular benef
glimepiride generics 1, 2, 4 mg	1 mg PO once daily (1-8 mg/day)	\$325-\$830	Non-benefit
SODIUM GLUCOSE COTRANSPORTER 2 INHIBITORS (SG	LT2i)		
dapagliflozin Forxiga 5, 10 mg	5 mg PO once daily (5-10 mg/day)	\$1,080	Regular benefit
+ metformin Xigduo 5+850/1000 mg	1 tab PO BID	\$1,035	Non-benefit
empagliflozin Jardiance 10, 25 mg	10 mg PO once daily (10-25 mg/day)	\$1,090	
+ metformin Synjardy 5+500/850/1000 mg, 12.5+500/850/1000 mg	1 tab PO BID	\$1,125	Limited Coverage
canagliflozin Invokana 100, 300 mg	100 mg PO once daily (100-300 mg/day)	\$1,140	
+ metformin Invokamet 50+500/1000 mg, 150+500/1000 mg	1 tab PO BID	\$1,310	Non-benefit
GLUCAGON LIKE PEPTIDE RECEPTOR AGONISTS (GLP1a)		1
semaglutide Ozempic 1.34 mg/mL: 1.5 mL (0.25, 0.5 mg/dose), 3 mL (1 mg/dose) multidose prefilled pens 2 mg/dose prefilled pen (not available)	0.25 mg subcut once weekly for 4 weeks, then ↑ to 0.5 mg/week (may titrate every 4 weeks to maximum dose of 2 mg/week)	\$2,870	Limited Coverage 2 mg dose: non-benet
semaglutide Rybelsus 3, 7, 14 mg tablets	3 mg orally once daily on an empty stomach for 30 days, then \uparrow to 7 mg/day (may \uparrow to 14 mg/day after subsequent 30 days)	\$2,750	Non-benefit
semaglutide Wegovy 0.25, 0.5, 1, 1.7 or 2.4 mg/dose single and multidose prefilled pens (not available) <i>Indication: chronic weight management</i>	0.25 mg subcut once weekly for 4 weeks without regard to meals (titrate every 4 weeks to maintenance dose of 2.4 mg/week)	N/A	Non-benefit
dulaglutide Trulicity 0.5 mL (0.75, 1.5 mg/dose) single dose prefilled pens 3 mg, 4.5 mg/dose prefilled pens (not available)	0.75 mg subcut once weekly (may ↑ to 1.5 mg/week after 1 week, then may titrate every 4 weeks to maximum dose of 4.5 mg/week)	\$2,990	Non-benefit
liraglutide Victoza 6 mg/mL: 3 mL (0.6, 1.2, 1.8 mg/dose) multidose prefilled pens	0.6 mg subcut once daily for 1 week, then \uparrow to 1.2 mg/day (may \uparrow to 1.8 mg/day after 1 week)	\$3,825	Non-benefit
liraglutide Saxenda 6 mg/mL: 3 mL (0.6, 1.2, 1.8, 2.4, 3 mg/dose) multidose prefilled pens <i>Indication: chronic weight management</i>	0.6 mg subcut once daily (titrate to maintenance dose of 3 mg/day in weekly intervals: discontinue after 12 weeks if ≥ 5% of initial body weight not lost)	\$5,120	Non-benefit
lixisenatide Adlyxine 50 mcg/mL: 3 mL (10 mcg/dose), 100 mcg/mL: 3 mL (20 mcg/dose) multidose prefilled pens	10 mcg subcut once daily for 14 days within 1 hour prior to meal (then \uparrow to maintenance dose of 20 mcg/day)	\$1,500	Non-benefit
BASAL INSULIN + GLP1 AGONIST FIXED-DOSE COMBINA	ATIONS [†]		
insulin degludec + liraglutide Xultophy 100 units/mL + 3.6 mg/mL: 3 mL (1 unit insulin degludec + 0.036 mg liraglutide) multidose prefilled pens	(10-50 units insulin degludec + 0.36-1.8 mg liraglutide subcut/day) [†]	\$4,060	Non-benefit
insulin glargine + lixisenatide Soliqua 100 units/mL + 33 mcg/mL: 3 mL (1 unit insulin glargine + 0.33 mcg lixisenatide) multidose prefilled pens (SoloSTAR)	do not exceed lixisenatide 10 mcg subcut/day initially (15-60 units insulin glargine + 5-20 mcg lixisenatide subcut/day within 1 hour prior to first meal) [†]	\$3,025	Non-benefit

McKesson Canada January 10, 2023; ²US Food and Drug Administration Glucophage (metformin); *Plan W exceptions: see FNHA Summary of Diabetes Drugs †Basal insulin + GLP1 agonist combinations: see Health Canada Drug Product Monographs for complex dosing instructions which take into account prior basal insulin dose

This document has been compiled for the British Columbia Ministry of Health's Pharmaceutical, Laboratory and Blood Services Division. The information contained in this document is intended for educational purposes only and is not intended as a substitute for the advice or professional judgment of a health care professional. The information in this document is provided without any express or implied warranty regarding its content, and no party involved with the preparation of this document is responsible for any errors or omissions that may be contained herein, nor is any party involved with the preparation of this document. Any use of this document will imply acknowledgement of this disclaimer and release the Province of British Columbia, its employees, agents and any party involved in the preparation of this document from any and all liability. Copyright © 2023, Province of British Columbia. All rights reserved.

BC Provincial Academic Detailing Service Email: PAD@gov.bc.ca Web: www.bcpad.ca

Dad Type 2 Diabetes Medications Marketed in Canada (v. Jan 27, 2023)

PAD Refills February 2023

Generic name, brand name, available strengths	Health Canada adult starting dose (range) ¹ See Canadian monographs for titration details	Approximate annual cost ² BC PharmaCare coverage			
DIPEPTIDYL PEPTIDASE 4 INHIBITORS (DPP4i)					
linagliptin Trajenta 5 mg	5 mg PO once daily (5 mg/day)	\$940	Limited Coverage		
+ metformin Jentadueto 2.5+500/850/1000 mg	1 tab PO BID	\$990			
saxagliptin Onglyza, generics 2.5, 5 mg	5 mg PO once daily (2.5-5 mg/day)	\$500-\$600	- Limited Coverage		
+ metformin Komboglyze 2.5+500/850/1000 mg	1 tab PO BID	\$1,015			
alogliptin Nesina 6.25, 12.5, 25 mg	25 mg PO once daily (6.25-25 mg/day)	\$870	Non-benefit		
+ metformin Kazano 12.5+1000 mg	1 tab PO BID	\$945			
sitagliptin Januvia, generics 25, 50, 100 mg	100 mg PO once daily (25-100 mg/day)	\$1,000	- - Non-benefit		
+ metformin Janumet, generics 50+500/850/1000 mg	1 tab PO BID	\$1,195			
+ metformin XR Janumet XR, generics 50+500/ 1000 mg, 100+1000 mg	50+500/1000 mg: 2 XR tabs PO once daily 100+1000 mg: 1 XR tab PO once daily	\$1,195			
MEGLITINIDE ANALOGUE					
repaglinide GlucoNorm, generics 0.5, 1, 2 mg	0.5 mg PO TID (1.5-16 mg/day)	\$250-\$770	Non-benefit		
THIAZOLIDINEDIONES (TZD)					
pioglitazone generics 15, 30, 45 mg	15 mg PO once daily (15-45 mg/day)	\$185-\$390	Limited Coverage		
rosiglitazone generics 2, 4, 8 mg	4 mg PO once daily or 2 mg PO BID (4-8 mg/day)	\$760-\$1,085	Non-benefit		
ALPHA-GLUCOSIDASE INHIBITOR					
acarbose Glucobay, generics 50, 100 mg	50 mg PO once daily (150-300 mg/day)	\$90-\$375	Non-benefit		
PO oral; BID twice a day; XR extended-release; TID three times a day; ¹ Heath Canada Drug Product Database; ² Cost range: includes initial to maximum dose without mark-up or professional fee calculated from McKesson Canada January 10, 2023; *Plan W exceptions: see FNHA Summary of Diabetes Drugs					

Generic name, brand name, available strengths, dosage forms ¹		Cost per 100 units BC PharmaCare coverage ²		
BASAL INSULINS				
insulin NPH 100 units/mL Humulin N, Novolin ge NPH vial, cartridges, prefilled pens (KwikPen)	< \$5	Regular benefit		
insulin glargine biosimilar 100 units/mL Basaglar cartridges, prefilled pens (KwikPen)	< \$10	Limited Coverage Plan W regular benefit		
insulin glargine biosimilar 100 units/mL Semglee cartridges, prefilled pens		Non-benefit		
insulin glargine 100 units/mL Lantus vial, cartridges, prefilled pens (SoloSTAR)	< \$10	Non-benefit		
insulin glargine 300 units/mL Toujeo prefilled pens (SoloSTAR, DoubleSTAR)	< \$10	Non-benefit		
insulin detemir 100 units/mL Levemir cartridges, prefilled pens (FlexTouch)	< \$10	Limited Coverage		
insulin degludec 100 units/mL, 200 units/mL Tresiba prefilled pens (FlexTouch)	< \$10	Non-benefit		
BOLUS (PRANDIAL) INSULINS				
insulin regular 100 units/mL Humulin R, Novolin ge Toronto vial, cartridges, prefilled pens (KwikPen ^{non-benefit})	< \$5	Regular benefit		
insulin regular 500 units/mL Entuzity basal + bolus activity, prefilled pens (KwikPen)	< \$5	Regular benefit		
insulin aspart biosimilar 100 units/mL Trurapi, Kirsty vial, cartridges, prefilled pens (SoloSTAR), prefilled pens	< \$5	Regular benefit		
insulin aspart 100 units/mL NovoRapid vial, cartridges, prefilled pens (FlexTouch)	< \$5	Non-benefit**		
insulin aspart 100 units/mL Fiasp vial, cartridges, prefilled pens (FlexTouch)	< \$5	Non-benefit		
insulin glulisine 100 units/mL Apidra vial, cartridges, prefilled pens (SoloSTAR)	< \$5	Regular benefit		
insulin lispro biosimilar 100 units/mL Admelog vial, cartridges, prefilled pens (SoloSTAR)	< \$5	Regular benefit		
insulin lispro 100 units/mL Humalog vial, cartridges, prefilled pens (KwikPen, Junior KwikPen)	< \$5	Non-benefit**		
insulin lispro 200 units/mL Humalog prefilled pens (KwikPen)	< \$5	Non-benefit		
BASAL + BOLUS INSULINS				
insulin regular + NPH Humulin 30/70, Novolin ge 30/70, 40/60, 50/50 100 units/mL vial, cartridges	< \$5	Regular benefit		
insulin aspart + aspart protamine 100 units/mL NovoMix 30 cartridges		Non-benefit		
insulin lispro + lispro protamine 100 units/mL Humalog Mix25, Mix50 cartridges, prefilled pens (KwikPen)	< \$5	Non-benefit		
NPH neutral protamine Hagedorn; ¹ Heath Canada Drug Product Database; ² Cost per 100 units without mark-up: calculated from McKesson Canada January 1 Professional Service Area retail drug and does not require a prescription); *Plan W exceptions: see FNHA Summary of Diabetes Drugs; **see BC PharmaCare				

This document has been compiled for the British Columbia Ministry of Health's Pharmaceutical, Laboratory and Blood Services Division. The information contained in this document is intended for educational purposes only and is not intended as a substitute for the advice or professional judgment of a health care professional. The information in this document is provided without any express or implied warranty regarding its content, and no party involved with the preparation of this document is responsible for any errors or omissions that may be contained herein, nor is any party involved with the preparation of this document esponsible for the result obtained from the use of information in this document will imply acknowledgement of this disclaimer and release the Province of British Columbia, its employees, agents and any party involved in the preparation of this document from any and all liability. Copyright © 2023, Province of British Columbia. All rights reserved.

coverage information and exceptions

BC Provincial Academic Detailing Service Email: PAD@gov.bc.ca Web: www.bcpad.ca